Trastuzumab emtansine (T-DM1) is highly effective in preventing stage 1 HER2-positive breast cancer from recurring – MedEdge MEA
MedEdge MEA shared a post on LinkedIn: .
“A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.
In a clinical trial involving 512 patients with the earliest stage of breast cancer that tested positive for the HER2 protein, 97% of those treated with trastuzumab emtansine (T-DM1) after surgery were alive and free of invasive cancer five years after treatment. The results, published online today in the Journal of Clinical Oncology (American Society of Clinical Oncology (ASCO)), suggest that T-DM1 is a reasonable treatment approach for this stage 1 population, the study authors say.
‘The ATEMPT trial has taught us that one year of T-DM1 after surgery for patients with a stage 1 HER2-positive cancer leads to outstanding long term outcomes, making it a reasonable treatment approach for select patients’, says senior author Sara Tolaney, MD, MPH, Chief, Division of Breast Oncology, Dana-Farber Cancer Institute.
Genentech, Gloria Spivak Faculty Advancement Fund, and Susan G. Komen supported the trial.”
Source: MedEdge MEA/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023